RICHARD SYD KORNBLUTH

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi Multimeric soluble CD40 ligand and GITR ligand as adjuvants for human immunodeficiency virus DNA vaccines
    Geoffrey W Stone
    Department of Medicine 0679, Stein Clinical Sciences Bldg, Room 304, University of California, San Diego, 9500 Gilman Dr, La Jolla, CA 92093 0679, USA
    J Virol 80:1762-72. 2006
  2. ncbi Enhancement of the priming efficacy of DNA vaccines encoding dendritic cell-targeted antigens by synergistic toll-like receptor ligands
    Claudius Grossmann
    Department of Molecular and Medical Virology, Ruhr Universitat Bochum, Universitatsstrasse 150, 44801 Bochum, Germany
    BMC Immunol 10:43. 2009
  3. ncbi CD40 ligand (CD154) stimulation of macrophages to produce HIV-1-suppressive beta-chemokines
    R S Kornbluth
    Department of Medicine, University of California, San Diego, and Department of Veterans Affairs Medical Center, La Jolla, CA 92093, USA
    Proc Natl Acad Sci U S A 95:5205-10. 1998
  4. ncbi An expanding role for CD40L and other tumor necrosis factor superfamily ligands in HIV infection
    Richard S Kornbluth
    University of California, San Diego, and the San Diego Veterans Affairs Healthcare System, La Jolla 92093, USA
    J Hematother Stem Cell Res 11:787-801. 2002
  5. ncbi Immunostimulatory combinations: designing the next generation of vaccine adjuvants
    Richard S Kornbluth
    Department of Medicine, University of California San Diego, 9500 Gilman Dr, 0679, La Jolla, CA 92093 0679, USA
    J Leukoc Biol 80:1084-102. 2006

Research Grants

  1. Regulation of HIV-1 Preintegration Complexes (PICs)
    RICHARD KORNBLUTH; Fiscal Year: 2002
  2. TNFSF APC activators for HIV Vaccines
    RICHARD KORNBLUTH; Fiscal Year: 2003
  3. Combined TNFSF and TLR stimulation of HIV vaccines
    RICHARD KORNBLUTH; Fiscal Year: 2006
  4. Vaccines to Generate Neutralizing Anti-HIV Antibodies
    RICHARD KORNBLUTH; Fiscal Year: 2007

Collaborators

Detail Information

Publications5

  1. ncbi Multimeric soluble CD40 ligand and GITR ligand as adjuvants for human immunodeficiency virus DNA vaccines
    Geoffrey W Stone
    Department of Medicine 0679, Stein Clinical Sciences Bldg, Room 304, University of California, San Diego, 9500 Gilman Dr, La Jolla, CA 92093 0679, USA
    J Virol 80:1762-72. 2006
    ..In summary, multimeric CD40L and GITRL are new adjuvants for DNA vaccines. Plasmids for expressing multimeric TNFSF fusion proteins permit the rapid testing of TNFSF molecules in vivo...
  2. ncbi Enhancement of the priming efficacy of DNA vaccines encoding dendritic cell-targeted antigens by synergistic toll-like receptor ligands
    Claudius Grossmann
    Department of Molecular and Medical Virology, Ruhr Universitat Bochum, Universitatsstrasse 150, 44801 Bochum, Germany
    BMC Immunol 10:43. 2009
    ....
  3. ncbi CD40 ligand (CD154) stimulation of macrophages to produce HIV-1-suppressive beta-chemokines
    R S Kornbluth
    Department of Medicine, University of California, San Diego, and Department of Veterans Affairs Medical Center, La Jolla, CA 92093, USA
    Proc Natl Acad Sci U S A 95:5205-10. 1998
    ..This pathway may play a role in anti-HIV-1 immunity and the development of immunologic reactions or lesions...
  4. ncbi An expanding role for CD40L and other tumor necrosis factor superfamily ligands in HIV infection
    Richard S Kornbluth
    University of California, San Diego, and the San Diego Veterans Affairs Healthcare System, La Jolla 92093, USA
    J Hematother Stem Cell Res 11:787-801. 2002
    ..New strategies are being developed to translate the profoundly immunostimulatory effects of CD40L found in animal models to humans with HIV infection...
  5. ncbi Immunostimulatory combinations: designing the next generation of vaccine adjuvants
    Richard S Kornbluth
    Department of Medicine, University of California San Diego, 9500 Gilman Dr, 0679, La Jolla, CA 92093 0679, USA
    J Leukoc Biol 80:1084-102. 2006
    ..Taken together, these new approaches provide significant incremental progress in the development of vaccines to elicit cell-mediated immunity against HIV and other pathogens...

Research Grants5

  1. Regulation of HIV-1 Preintegration Complexes (PICs)
    RICHARD KORNBLUTH; Fiscal Year: 2002
    ..New tools and concepts will be gained, and precise molecular targets for anti-HIV drug design will come into focus. ..
  2. TNFSF APC activators for HIV Vaccines
    RICHARD KORNBLUTH; Fiscal Year: 2003
    ..Upon the completion of these feasibility studies, it will be clear if these concepts should be advanced into more extensive vaccine studies both for HIV and other pathogens. ..
  3. Combined TNFSF and TLR stimulation of HIV vaccines
    RICHARD KORNBLUTH; Fiscal Year: 2006
    ..In addition, this DNA vaccine approach may prove generally applicable for emerging infections and other diseases for which a potent vaccine is needed. ..
  4. Vaccines to Generate Neutralizing Anti-HIV Antibodies
    RICHARD KORNBLUTH; Fiscal Year: 2007
    ..While this research is focused on HIV, the same immunostimulants could be applied to vaccines against many other infections including influenza, viral hepatitis, West Nile virus, smallpox, and agents of biodefense significance. ..